Form 4: Corbus Pharmaceuticals' Chief Medical Officer Receives Stock Options and Restricted Stock Units

Dominic Smethurst, Chief Medical Officer of Corbus Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Summary

• Dominic Smethurst, the Chief Medical Officer of Corbus Pharmaceuticals Holdings, Inc., reported changes in beneficial ownership on February 4, 2025.
• On January 31, 2025, Smethurst was granted 27,200 restricted stock units (RSUs) that will be settled in shares of common stock.
• These RSUs vest 25% annually, starting on January 31, 2026.
• Smethurst also acquired stock options for 91,200 shares with an exercise price of $9.79, also granted on January 31, 2025.
• 25% of these options vest on January 31, 2026, with the remaining 75% vesting monthly over 36 months starting February 28, 2026.
• Following these transactions, Smethurst directly owns 77,200 shares of common stock, including unvested RSUs.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future. The grant of equity suggests a positive outlook, but it's a routine filing, hence the moderate score.

Positives

• The grant of RSUs and stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule of the RSUs and stock options incentivizes long-term commitment and performance.

Industry Context

Equity compensation is a common practice in the pharmaceutical industry to attract and retain key executives and align their interests with those of the company's shareholders.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in publicly traded pharmaceutical companies.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use similar equity-based compensation plans.
• The vesting schedules described are typical, designed to incentivize long-term performance and retention.

Stakeholder Impact

• The equity grants align management's interests with shareholders, potentially driving long-term value creation.
• Employees may view the equity grants as a positive sign of the company's commitment to its leadership.

Key Dates